Atenolol-Induced Triglyceride Elevation

Mechanism and Clinical Significance

Atenolol increases triglycerides primarily by reducing lipoprotein lipase (LPL) activity and increasing hepatic VLDL production through beta-adrenergic blockade, which impairs the normal breakdown of triglyceride-rich lipoproteins, according to the American Heart Association 1, 2
The American Heart Association classifies beta-blockers like atenolol among drugs that may cause very high triglycerides associated with pancreatitis risk when combined with other risk factors 1
Nonselective beta-blockers and atenolol lower HDL cholesterol, increase triglycerides, and may cause type-2 diabetes in hypertensive patients, as noted by the American Heart Association and other guideline societies 2

Atenolol showed inferior cardiovascular outcomes compared to losartan (LIFE trial) and amlodipine (ASCOT trial), with untoward metabolic effects similar to nonselective beta-blockers, according to the European Society of Cardiology 5, 2
Vasodilating beta-blockers like carvedilol and nebivolol have less or no dysmetabolic action and reduced incidence of new-onset diabetes compared to atenolol, as recommended by the European Society of Cardiology 5, 2

For patients with metabolic syndrome, multiple metabolic risk factors, abdominal obesity, impaired fasting glucose, or existing hypertriglyceridemia, atenolol should not be preferred—choose vasodilating beta-blockers instead, according to the American Heart Association and the European Society of Cardiology 5, 2
If triglycerides become elevated (≥150 mg/dL) or if metabolic syndrome develops, switch to carvedilol or nebivolol rather than continuing atenolol, as recommended by the American Heart Association 2
Consider adding fibrates (30-50% triglyceride reduction) or omega-3 fatty acids (20-50% reduction) to manage hypertriglyceridemia if beta-blockade must continue with atenolol, according to the American Heart Association 7